BridgeBio Pharma to Share Further Insights on Acoramidis Study for Transthyretin Amyloid Cardiomyopathy at 2024 ISA Meeting

A biopharmaceutical company specializing in genetic diseases and cancers has unveiled plans to present a series of findings at the 2024 International Symposium on Amyloidosis (ISA) in Rochester, Minnesota, from May 26 to May 30, 2024.

BridgeBio Pharma will showcase 12 oral and moderated poster presentations during the event. Additionally, they will hold an investor call on May 29, 2024, at 5:30 pm ET to delve into recent analyses and favorable data from the Phase 3 trial of ATTRibute-CM, as well as emerging real-world evidence in ATTR-CM. Notable speakers during the investor call include Mathew Maurer, M.D. from Columbia University Irving Medical Center and Ahmad Masri, M.D., M.S. from Oregon Health & Science University.

To access the presentations subsequent to BridgeBio’s participation at the 2024 ISA, interested parties can visit

Key oral and moderated poster presentations include:

  1. The correlation between early serum transthyretin level increase and improved survival in ATTR cardiomyopathy.
  2. The association between Acoramidis treatment-related serum TTR increase and reduced cardiovascular mortality in ATTR-CM.
  3. The relationship between Acoramidis treatment-related serum TTR increase and decreased risk of cardiovascular hospitalization in ATTR-CM patients.
  4. Early reduction in cardiovascular death or hospitalization achieved by Acoramidis in transthyretin amyloid cardiomyopathy, as demonstrated in the ATTRibute-CM clinical trial.
  5. Higher mortality risk in previously hospitalized patients, as revealed in ATTRibute-CM.
  6. Acoramidis’s positive impact on clinical outcomes in transthyretin amyloid cardiomyopathy.
  7. Sensitivity analysis and sub-analysis comparing Acoramidis and placebo in stage 4 CKD in ATTRibute-CM.
  8. Acoramidis’s influence on health-related quality of life in ATTR-CM patients.
  9. Improvement in health-related quality of life in Acoramidis-treated patients with ATTR-CM, as evidenced by improvements in KCCQ scores.
  10. Acoramidis’s effect on biomarkers of clinical relevance in ATTR-CM, particularly NT-proBNP indices.
  11. Acoramidis’s potential to enhance cardiac function and induce regression in ATTR-CM, as indicated by data from the ATTRibute-CM cardiac magnetic resonance (CMR) substudy.
  12. The rationale and design of ACT-EARLY, the Acoramidis transthyretin amyloidosis prevention trial.

These presentations aim to provide comprehensive insights into Acoramidis’s efficacy and potential in treating transthyretin amyloid cardiomyopathy and related conditions.

Source Link

Newsletter Updates

Enter your email address below and subscribe to our newsletter